NCT04260802: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers |
|
|
| Recruiting | 1/2 | 116 | Canada | OC-001, Drug: OC-001 in Combination with Avelumab | Ocellaris Pharma, Inc. | Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer | 03/26 | 09/26 | | |
